Antalya Training and Research Hospital
Antalya, Turkey (Türkiye)
Location status: Recruiting
Recruiting
NCT Number: NCT05979675
Acute Myeloid Leukemia Registry
All acute myeloid leukemia (AML) patients diagnosed after 1 Jan 2020 will be included to this study.
Recruiting
Interested in participating?
Request InfoKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
About this study
This is a non interventional prospective disease registry, 250 prospective patients diagnosed with AML across 20 centers in Turkey.
Participating sites will consist of hematology clinics and routine follow-up procedures will be followed-up.
All patients diagnosed after 1 Jan 2020 as AML will be included and patients will be enrolled during 24 months of period and will be followed-up 36 months. Study will be completed in 60 months.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Diagnosed as AML after 1 Jan 2020
- Patients signed informed consent form
Exclusion criteria
- Patients under 18 years old
Treatment and study plan
Primary outcomes
-
Overall Survival
Time frame: 60 months
From diagnosis to exits by any cause
Study contacts
Contact information is provided by the study sponsor or research team.
Ilker Kurkcu
CONTACT
Volkan Karakus, Assoc. Prof.
CONTACT
Sponsors and collaborators
Lead sponsor
Turkish Hematology Association
Other
Registry information
Official study title
Acute Myeloid Leukemia Registry - Prospective National Multicentric Observational Study
Acronym: AMLREGISTRY
Important dates
- Study start
- 2021
- Primary completion
- 2026
- Study completion
- 2026
- First posted
- Aug 7, 2023
- Registry last updated
- Aug 7, 2023
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Recruiting
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
NCT05554406
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Birmingham, Alabama, United States
View Trial Details
Recruiting
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
NCT06317649
Acute Myeloid Leukemia, Hematologic Diseases
Birmingham, Alabama, United States
View Trial Details
Recruiting
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT07306832
Acute Myeloid Leukemia, Disease Attributes
Palo Alto, California, United States
View Trial Details
Recruiting
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
NCT06672146
Acute Myeloid Leukemia, Hematologic Diseases
Tucson, Arizona, United States
View Trial Details